Please assess the completion status of the following clinical trial:

Trial Title: Erlotinib in Treating Women Undergoing Surgery For Stage I, Stage II, or Stage III Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion~* Cytologically or histologically confirmed adenocarcinoma of the breast~  * Stage I-III disease~ * BI-RADS 4 or 5 abnormalities on breast imaging and undergoing core needle biopsy for diagnosis~ * Participants must have a lesion of at least 1-cm on breast imaging studies (mammogram, ultrasound, or MRI)~ * Participants must have breast cancer amenable to surgery with curative intent and must have agreed to undergo such surgery~    * The surgical procedure must be scheduled in the near future to accommodate a treatment period of no less and no more than 15 days~* Clinically positive for the overexpression of EGFR and interleukin-1α~* Clinically negative for expression of the estrogen receptor (ER-negative) and progesterone receptor (PgR-negative)~  * May be positive or negative for HER2~Exclusion~* Locally advanced or metastatic disease not amenable to surgery~* Known brain metastases~PATIENT CHARACTERISTICS:~Inclusion~* Female~* Menopausal status not specified~* ECOG performance status (PS) 0-2 or Karnofsky PS 60-100%~* ANC ≥ 1000/mm³~* Platelet count ≥ 75,000/mm³~* AST and ALT ≤ 2.5 times upper limits of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Bilirubin ≤ 2 times ULN~* Hemoglobin \> 9 g/dL~* Creatinine within normal institutional limits OR creatinine clearance \>60 mL/min~* Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and women within 6 months of menopause~* Women of child-bearing potential and their partners must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation~Exclusion~* Pregnant or nursing~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to erlotinib hydrochloride~* Uncontrolled intercurrent illness including, but not limited to, any of the following:~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Psychiatric illness/social situations that would limit compliance with study requirements~PRIOR CONCURRENT THERAPY:~Exclusion~* Received any other therapy (i.e., surgery, radiation, hormone treatment, biologic therapy, and/or chemotherapy) for the treatment of breast cancer~* Concurrent use of anti-neoplastic or anti-tumor agents not part of the study therapy, including chemotherapy, radiation therapy, immunotherapy, and hormonal anticancer therapy~* Receiving any other investigational agents

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- erlotinib hydrochloride (Type: EXPERIMENTAL): Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues